Abbott Laboratories [NYSE: ABT] closed the trading session at $116.99.
The stocks have a year to date performance of 6.29 percent and weekly performance of -0.22 percent. The stock has been moved at 9.26 percent over the last six months. The stock has performed 2.89 percent around the most recent 30 days and changed 12.58 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 5.65M shares, ABT reached to a volume of 8302875 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Abbott Laboratories [ABT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $130.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 1.76. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on October 08, 2024. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on September 19, 2024, representing the official price target for Abbott Laboratories stock.
The Average True Range (ATR) for Abbott Laboratories is set at 1.93, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 4.94. The Price to Book ratio for the last quarter was 5.18, with the Price to Cash per share for the same quarter was set at 4.15. Price to Free Cash Flow for ABT in the course of the last twelve months was 36.00 with Quick ratio for the last quarter at 1.18.
ABT stock trade performance evaluation
Abbott Laboratories [ABT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.22. With this latest performance, ABT shares gained by 2.89% in over the last four-week period, additionally plugging by 9.26% over the last 6 months – not to mention a rise of 22.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 56.45, with the RSI for the last a single of trading hit 55.47, and the three-weeks RSI is set at 56.81 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 114.05, while it was recorded at 117.63 for the last single week of trading, and 110.48 for the last 200 days.
Abbott Laboratories [ABT]: An insightful look at the core fundamentals
Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.18 and a Current Ratio set at 1.68.
Earnings per share (EPS) analysis for Abbott Laboratories [ABT] stock
With the latest financial reports released by the company, Abbott Laboratories posted 1.19/share EPS, while the average EPS was predicted by analysts to be reported at 1.19/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 9.50%.
Abbott Laboratories [ABT]: Institutional Ownership
There are presently around $79.56%, or 79.98%% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 166.35 million shares, which is approximately 9.5932%. BLACKROCK INC., holding 131.13 million shares of the stock with an approximate value of $$13.63 billion in ABT stocks shares; and BLACKROCK INC., currently with $$7.73 billion in ABT stock with ownership which is approximately 4.2903%.
